Clinical trials · San Francisco, CA
Small Cell Lung Cancer clinical trials in San Francisco
We’re tracking 93 recruiting small cell lung cancer studies with a site in or near San Francisco — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near San Francisco
- NCT03816345RecruitingPhase 1
Nivolumab for advanced cancer with autoimmune conditions
This Phase 1 study tests nivolumab, an immunotherapy “anti-cancer accelerator,” in people with advanced cancer who also have an autoimmune disorder. It aims to see if nivolumab can be given safely and whether it may help shrink or control cancer.
Palo Alto, CaliforniaAges 18 years+ - NCT07219251Recruiting
Veterans with lung cancer needed for study
This study wants to learn more about the experiences of veterans with lung cancer. If you are receiving cancer treatment or recently finished it, you may be able to join.
Palo Alto, CaliforniaAges 18 years+ - NCT05176483RecruitingPhase 1
Zanzalintinib with immunotherapy for advanced solid tumors
This Phase 1 study tests zanzalintinib (a targeted medicine) combined with immunotherapy medicines in people with advanced solid cancers that can’t be removed by surgery. It aims to see if the combination can control the cancer and determine the safest dose.
Palo Alto, CaliforniaAges 18 years+ - NCT04981119Recruiting
Test apheresis for CAR T manufacturing in HLA-A2 solid tumors
This trial studies how a process called apheresis is used to make CAR T cells for people with certain solid tumors. It is designed for tumors that have lost a specific immune marker (HLA-A*02), which may affect how well CAR T therapies work.
Palo Alto, CaliforniaAges 18 years+ - NCT06562192RecruitingPhase 1
Testing a radioactive drug for advanced pancreatic, lung, breast, and colorectal cancers
This trial tests a new radioactive drug (177Lu-NNS309) for people with advanced pancreatic, lung, breast, or colorectal cancer that has not responded to prior treatments. It aims to see if the drug can target and shrink tumors.
Palo Alto, CaliforniaAges 18–100 - NCT06681220RecruitingPhase 1/Phase 2
Temozolomide and stenoparib for relapsed small cell lung cancer
This trial tests two drugs—temozolomide and stenoparib—for people with small cell lung cancer that has returned after initial chemo. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Palo Alto, CaliforniaAges 18 years+ - NCT06080061RecruitingPhase 1
Personalized radiation and chemo for lung cancer
This trial is testing a personalized approach to giving radiation and chemotherapy together for lung cancer. It aims to make treatment more effective by tailoring the radiation schedule to each person.
Palo Alto, CaliforniaAges 18 years+ - NCT06128551RecruitingPhase 1/Phase 2
Testing two targeted drugs for KRAS G12C advanced cancer
This study tests two oral medicines (elironrasib and daraxonrasib) given alone or together to see if they can shrink tumors or slow down cancer growth in people with advanced solid tumors that have a KRAS G12C mutation. It is for people who have already tried other treatments.
Stanford, CaliforniaAges 18 years+ - NCT04282044RecruitingPhase 1
CRX100 drug trial for advanced cancers with or without pembrolizumab
This Phase 1 trial tests CRX100 (a new cancer medicine) alone and with pembrolizumab (an immune checkpoint drug) in people with advanced solid tumors. It’s mainly designed to check safety and side effects, and to see whether tumors respond, potentially helping people whose cancer has come back or stopped responding to standard treatment.
Stanford, CaliforniaAges 18 years+ - NCT05498428RecruitingPhase 2
Amivantamab for advanced lung cancer with EGFR mutations
This Phase 2 study tests amivantamab (an antibody medicine) in people with advanced or metastatic non-small cell lung cancer that has specific EGFR gene changes. It may help shrink tumors or control cancer when standard curative treatments aren’t possible.
Stanford, CaliforniaAges 18 years+ - NCT07046923RecruitingPhase 1
A study of LY4175408 for advanced cancer
This trial tests a new targeted drug (LY4175408) for people with certain advanced solid tumors (lung, endometrial, or triple negative breast cancer) who have already tried standard treatments. The goal is to see if the drug is safe and effective.
Stanford, CaliforniaAges 18 years+ - NCT05866302Recruiting
CT breathing-scan test to detect chronic lung injury after transplant
This study uses a special way to analyze breathing-related CT images to find early or ongoing lung injury after an allogeneic stem cell transplant. It may help clinicians recognize chronic lung complications sooner and better guide care.
Stanford, CaliforniaAges 3 years+ - NCT01385722Enrolling by invitation
Molecular testing for cancers in the chest
This study looks at the genetic changes (molecular analysis) in certain cancers of the chest. It may help doctors learn more about what drives these cancers and how they might be diagnosed or treated in the future.
Stanford, CaliforniaAges 18 years+ - NCT04683250RecruitingPhase 1/Phase 2
RET-targeting drug study for advanced cancers with RET changes
This trial tests an “RET-inhibitor” medicine (TAS0953/HM06) for advanced solid tumors that have RET gene changes. It may help shrink tumors by blocking cancer growth signals from the RET gene.
Stanford, CaliforniaAges 18 years+ - NCT04585490RecruitingPhase 3
Testing a personalized add-on treatment after stage III lung cancer
This phase 3 trial tests whether tailoring the next (add-on) treatments can improve outcomes after standard chemoradiation and immunotherapy for stage III, unresectable (not operable) non-small cell lung cancer. It specifically looks at giving durvalumab plus an additional drug (tremelimumab) and possibly other consolidation chemotherapy based on a personalized plan.
Stanford, CaliforniaAges 18 years+ - NCT00568490Recruiting
Finding blood markers that show low oxygen in tumors
This study looks for substances in blood that may reflect how “low-oxygen” a tumor is. If you have head and neck cancer or non-small cell lung cancer, it may help researchers understand tumor oxygen levels and improve future care.
Stanford, CaliforniaAges 18 years+ - NCT07111520RecruitingPhase 1/Phase 2
Testing a new drug combination for advanced lung cancer
This trial tests whether a combination of two experimental drugs, BNT326 and BNT327, is safe and could help people with advanced non-small cell lung cancer (NSCLC) that has spread or cannot be removed. It is for people who have already had some treatment or are starting their first treatment, depending on the group.
Stanford, CaliforniaAges 18 years+ - NCT06051695RecruitingPhase 1/Phase 2
CAR T cell therapy for mesothelin-positive solid tumors
This trial tests a new type of immune cell therapy (CAR T-cells) designed to target cancer cells that have a protein called mesothelin but have lost a marker that lets them hide from the immune system. It's for people with advanced solid tumors who have already tried standard treatments.
Stanford, CaliforniaAges 18 years+ - NCT06706076RecruitingPhase 1/Phase 2
New drug for NSCLC with EGFR or HER2 mutations
This trial tests a new medication, BH-30643, for people with non-small cell lung cancer that has spread and has specific EGFR or HER2 gene changes. The goal is to see if this treatment can shrink tumors after other standard therapies have been tried.
Stanford, CaliforniaAges 18 years+ - NCT06060613RecruitingPhase 1/Phase 2
OBX-115 cell therapy for advanced melanoma or lung cancer
This trial tests an experimental cell therapy called OBX-115 for people with advanced melanoma or non-small cell lung cancer that has not responded to standard treatments. The therapy uses your own immune cells to fight the cancer. The study aims to see if it is safe and effective.
Stanford, CaliforniaAges 18 years+ - NCT05987644RecruitingPhase 1/Phase 2
Timing of brain radiation for ALK-positive lung cancer with brain mets
This trial tests whether it is better to delay brain radiation or give it right away in people with ALK-positive lung cancer that has spread to the brain and is causing few or no symptoms. If you are starting alectinib, you may be able to join and help find the best timing for radiation.
Stanford, CaliforniaAges 18 years+
Hear when a new Small Cell Lung Cancer trial opens near San Francisco, CA
We’ll email you when one opens near San Francisco, CA — at most once a week, no account needed, unsubscribe anytime.
Small Cell Lung Cancer trials in other cities
Where these studies are running near San Francisco
Institutions with a site for the recruiting small cell lung cancer studies listed above.
- Stanford University · 11 studies
- Stanford Cancer Institute · 5 studies
- Exelixis Clinical Site #123
- Stanford Cancer Center
- Stanford Health Care
- Stanford Medicine Cancer Center
- VA Palo Alto Health Care System
- Veterans Affairs Palo Alto
What taking part in a small cell lung cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting small cell lung cancer studies in California.
Common questions
- Are there small cell lung cancer clinical trials near San Francisco?
- Yes. We're currently tracking 93 recruiting small cell lung cancer studies with a site near San Francisco, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a small cell lung cancer study near San Francisco?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in San Francisco to take part?
- Not necessarily. These studies have a site near San Francisco, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a small cell lung cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New small cell lung cancer studies open near San Francisco regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.